MENU
DCTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Delcath Systems (DCTH) Earnings Date & Reports

Delcath Systems Inc is an oncology company... Show more

A.I. Advisor
published Earnings

DCTH is expected to report earnings to fall 182.35% to -14 cents per share on March 30

Delcath Systems DCTH Stock Earnings Reports
Q4'26
Est.
$-0.14
Q3'26
Beat
by $0.27
Q2'26
Beat
by $0.16
Q1'26
Beat
by $0.07
Q4'25
Beat
by $0.03
The last earnings report on November 09 showed earnings per share of 17 cents, beating the estimate of -10 cents. With 252.52K shares outstanding, the current market capitalization sits at 518.05M.
A.I.Advisor
Nov 09, 2026

Delcath Systems (DCTH) Q3 2026 Earnings Recap: HEPZATO Momentum Powers a Record Quarter

Key Takeaways

  • Total revenue reached $35.1 million in the third quarter of 2026, up about 71% year over year and well above the roughly $25.6 million consensus estimate.
  • Diluted earnings came in at $0.17 per share, a sharp reversal from the $0.10-per-share loss analysts had expected, with net income of $7.0 million.
  • HEPZATO KIT revenue climbed to $32.7 million on strong treatment-volume growth, while CHEMOSAT revenue nearly doubled to $2.4 million.
  • Gross margin expanded to 89%, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $11.5 million.
  • Management raised full-year 2026 revenue guidance to a range of $115 million to $117 million, up from $104 million to $108 million.
  • For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • Discover automated strategies and market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Delcath Systems is an interventional oncology company focused on liver-directed cancer treatments. Its U.S. commercial story centers on HEPZATO KIT, a combination drug-and-device therapy that delivers high-dose chemotherapy directly to the liver, alongside CHEMOSAT in Europe. Because the company is scaling a commercial launch from a small base, quarterly revenue growth, treatment-center activations, and new patient starts matter as much as the bottom line. This report also carries broader significance: it tests whether Delcath can translate rapid top-line expansion into consistent operating profitability while it funds a growing clinical pipeline. After consecutive quarters of beating estimates, investors were watching closely to see whether momentum could continue into the seasonally softer second half of the year.

Reported Results

Delcath reported total third-quarter 2026 revenue of $35.1 million, up roughly 71% from $20.6 million in the prior-year period and ahead of the approximately $25.6 million consensus estimate. HEPZATO KIT revenue rose to $32.7 million from $19.3 million, reflecting about 72% year-over-year treatment-volume growth, while CHEMOSAT revenue increased to $2.4 million from $1.3 million.

On a GAAP (Generally Accepted Accounting Principles) basis, the company posted net income of $7.0 million, or $0.17 per diluted share, compared with $0.8 million, or $0.02 per share, a year earlier. Analysts had projected a loss of about $0.10 per share, making the result a significant upside surprise. Gross margin expanded to 89% from 87%, and adjusted EBITDA rose to $11.5 million from $5.3 million. Operating cash flow was $8.2 million, and the company ended the quarter with $104.3 million in cash and investments and no debt.

Management raised full-year 2026 revenue guidance to $115 million to $117 million, up from the prior $104 million to $108 million range, and now expects at least 41% HEPZATO KIT volume growth for the year. The company also passed its 1,000th U.S. commercial HEPZATO treatment during the quarter and added two treatment centers, including AdventHealth, bringing active centers to 33.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Delcath Systems, it offers a structured way to identify comparable opportunities and monitor shifting momentum across the healthcare and oncology space.

Market Reaction and Investor Sentiment

Shares of Delcath Systems moved sharply higher following the report, rising more than 25% in early trading as investors responded to the revenue beat and the second guidance increase of the year. The upside reflected not only the top-line strength but also the quality of the result, with profit coming from core operations rather than interest income or tax items.

Still, sentiment was not entirely one-sided. Management's raised guidance implies a sequential revenue step-down in the fourth quarter, driven by holiday seasonality and a slower pace of new-patient starts. Slower-than-planned treatment-center activations and a slight easing in new patient starts per site remained points of debate, even as the company reiterated that new patient starts stayed above its planning assumption.

Forward Outlook and Key Factors to Monitor

Following this earnings event, investors will be watching whether Delcath can sustain treatment-volume growth while managing the seasonal softness management has flagged for the fourth quarter. The raised full-year guidance implies fourth-quarter revenue of roughly $25.8 million to $27.8 million, a notable step-down from the record third quarter, so execution against that range will be a near-term focus.

Commercial expansion remains a key driver. The company ended the quarter with 33 active treatment centers and expects at least 36 by year-end, and the addition of AdventHealth, a large integrated health system, could broaden referral volume over time. New patient starts per site, which eased to about 0.6 per month, will be a closely watched metric for gauging underlying demand.

On the cost side, research and development (R&D) and selling, general, and administrative (SG&A) expenses continue to rise as the company invests in clinical programs and its commercial footprint, which may make quarterly profitability uneven. Longer term, pipeline milestones matter: a colorectal cancer interim analysis is expected around mid-2027, an Investigational New Drug (IND) application for cholangiocarcinoma is planned for early 2027, and an oxaliplatin-based program is targeted to complete preclinical work by mid-2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations